A Meta-Analysis of Mismatch Negativity in Schizophrenia: From Clinical Risk to Disease Specificity and Progression.
A Meta-Analysis of Mismatch Negativity in Schizophrenia: From Clinical Risk to Disease Specificity and Progression.
复制标题
DOI：
10.1016/j.biopsych.2015.08.025
复制
发表时间：
2016-06-15
影响因子：
10.6
通讯作者：
Gold JM
中科院分区：
文献类型：
--
作者：
Erickson MA;Ruffle A;Gold JM
错配阴性（MMN）在精神分裂症中持续受损的观察结果引起了人们对使用这种生物标志物作为疾病风险和进展指数的极大兴趣。尽管有如此热情，但关于 MMN 损伤的性质的许多问题仍未解决。本研究通过检查一系列临床表现以及实验参数的损伤，扩展了早期对精神分裂症 MMN 损伤的荟萃分析。本研究纳入101例精神分裂症患者样本，包括首发（N=13）、慢性（N=13）和混合期（N=75）样本。此外，还对三种相关病症进行了 MMN 检查：双相情感障碍 (N=9)、未受影响的一级亲属 (N=8) 和临床高风险 (N=16)。我们发现 MMN 损伤 (1) 可能反映了临床高危人群疾病进展的脆弱性，而不是该疾病的遗传风险； (2) 与患病最初几年后的病程基本无关，表明损伤在整个生命周期中不会进行性进展； (3) 存在于躁郁症中，尽管程度低于精神分裂症； (4)不受实验参数的调节，例如标准音调与异常音调之间的变化幅度或异常音调的频率，但可能受注意力需求的调节。这些发现为更好地了解精神分裂症中 MMN 损伤的性质及其作为临床有用生物标志物的潜力奠定了基础。
The observation that mismatch negativity (MMN) is consistently impaired in schizophrenia has generated considerable interest in the use of this biomarker as an index of disease risk and progression. Despite such enthusiasm, a number of issues remain unresolved regarding the nature of MMN impairment. The present study expands upon an earlier meta-analysis of MMN impairment in schizophrenia by examining impairment across a range of clinical presentations, as well as across experimental parameters. One hundred and one samples of schizophrenia patients were included in the present study, including first-episode (N=13), chronic (N=13), and mixed-stage (N=75) samples. Additionally, MMN was examined in three related conditions: bipolar disorder (N=9), unaffected first-degree relatives (N=8), and clinical high risk (N=16). We found that MMN impairment (1) likely reflects a vulnerability to disease progression in clinical high risk populations rather than a genetic risk for the condition; (2) is largely unrelated to duration of illness after the first few years of illness, indicating that impairment is not progressive throughout the lifespan; (3) is present in bipolar disorder, albeit to a lesser degree than in schizophrenia; and (4) is not modulated by experimental parameters such as magnitude of change between standard and deviant tones or frequency of deviant tones, but may be modulated by attentional demands. Such findings lay the foundation for a better understanding of the nature of MMN impairment in schizophrenia, as well as its potential as a clinically useful biomarker.